Sound Pharmaceuticals, a privately held biotechnology company based in Seattle, announced on October 19, 2026, that a new analysis of its Phase 3 SPI-1005 clinical trial demonstrated statistically significant improvements in low-to-mid-frequency hearing among patients with Ménière’s disease. The research received Best in Scientific Orals recognition at the American Academy of Otolaryngology-Head and Neck Surgery’s 2026 Annual Meeting, taking place October 17 through October 20 in Los Angeles. The analysis examined whether patients achieved an average improvement of at least 10 decibels across selected frequencies following treatment with SPI-1005, an investigational oral formulation of ebselen. Sound Pharmaceuticals believes the results support further development for sudden sensorineural hearing loss, although the patients analyzed had Ménière’s disease rather than a confirmed sudden hearing loss indication.
The findings came from STOPMD-3, a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 221 adults with definite Ménière’s disease. Participants received SPI-1005 at 400 mg twice daily or matching placebo for 28 days, with hearing assessments continuing through Day 84. The new analysis found statistically significant differences favoring active treatment at multiple assessment points, including results from pure-tone audiometry and words-in-noise testing, with reported p-values below 0.01. However, the October announcement does not disclose the complete response rates, confidence intervals or patient denominators for the newly defined frequency-based analyses.
The latest presentation builds on the company’s previously reported pivotal results, which showed that 57.9% of SPI-1005 recipients achieved a defined low-frequency hearing improvement by Day 84, compared with 36.5% receiving placebo. Sound Pharmaceuticals also reported improvements in speech discrimination and continued clinical activity during an open-label extension. These results establish a rationale for studying the medicine in related hearing disorders, but they do not demonstrate that SPI-1005 is effective for acute sudden sensorineural hearing loss.
What did the new AAO-HNS analysis reveal about hearing improvement?
The newly presented analysis focused on hearing changes across three or four low-to-mid frequencies rather than relying only on a response at one selected low frequency. Investigators examined whether each ear achieved an average improvement of at least 10 decibels from baseline. Treatment responses were then compared between the SPI-1005 and placebo groups at Days 28, 56 and 84.
Sound Pharmaceuticals reported statistically significant differences at multiple time points, involving both pure-tone audiometry and words-in-noise measurements. The p-values were below 0.01 for several comparisons, suggesting that the observed differences would be unlikely under the relevant statistical assumptions if there were no treatment effect. However, statistical significance does not independently establish the clinical importance of the measured improvements.
The complete numerical results for this newer analysis were not included in the October 19 announcement. In particular, the company did not disclose the percentage of participants meeting the three-frequency or four-frequency response definitions at every time point. It would therefore be premature to assign the earlier 57.9% response rate to the new frequency-based endpoint.
The analysis nevertheless provides a different perspective on the pivotal dataset. Improvement across several adjacent frequencies may offer information about the breadth of hearing recovery, rather than a change confined to one measurement. Establishing whether such changes translate into better everyday communication remains an important clinical consideration.
What did the original STOPMD-3 randomized trial demonstrate?
STOPMD-3 enrolled 221 participants across 11 United States clinical sites after screening 254 individuals for eligibility. Patients had definite Ménière’s disease with active symptoms and were randomized to receive SPI-1005 or placebo. The controlled treatment phase lasted 28 days, with auditory and vestibular assessments continuing for approximately three months.
The company reported that its prespecified co-primary endpoints involving hearing improvement and speech discrimination were achieved. At Day 84, 57.9% of treated patients met the definition of at least a 10-decibel improvement at one low frequency, compared with 36.5% receiving placebo. The difference was statistically significant, with a reported p-value of 0.0037.
A stricter analysis requiring improvement at two adjacent low frequencies showed responses in 41.1% of the SPI-1005 group and 13.5% of placebo recipients. This represented approximately a threefold difference in the proportion meeting that particular response criterion, with a p-value below 0.0001. The numerical comparison was more pronounced under the stricter definition, although the proportions were smaller than for the single-frequency endpoint.
Speech discrimination was assessed using words-in-noise testing. At Day 84, 42.1% of the active-treatment group met the relevant response criterion, compared with 27.1% receiving placebo. The company reported a p-value of 0.0336 for that comparison.
These findings provide evidence of treatment activity within the studied Ménière’s population. However, the trial’s primary indication, enrollment criteria and clinical context remain distinct from sudden sensorineural hearing loss.
Why is sudden sensorineural hearing loss different from Ménière’s disease?
Sudden sensorineural hearing loss is generally characterized by a rapid decline in hearing over a short period, often developing within 72 hours. It frequently affects one ear and may occur without a clearly identifiable cause. Some patients also experience tinnitus, dizziness or vertigo, although these accompanying symptoms vary.
Ménière’s disease is a chronic inner ear disorder associated with episodes of vertigo, fluctuating hearing loss, tinnitus and a sensation of fullness or pressure in the affected ear. Hearing impairment often involves lower frequencies during earlier stages. Over time, some patients develop more persistent hearing loss and reduced speech understanding.
The conditions therefore share certain symptoms and aspects of auditory dysfunction, but their clinical course and underlying mechanisms are not identical. Ménière’s disease involves recurrent or fluctuating symptoms, while sudden sensorineural hearing loss is defined by an acute change that may represent a different pathological process.
This distinction is central to the interpretation of the new SPI-1005 analysis. A medicine that improves hearing in patients with Ménière’s disease might also have activity in other forms of inner ear injury, particularly if the underlying biological mechanisms overlap. However, that possibility must be tested in patients with the proposed new condition.
The October findings should consequently be regarded as supportive evidence for further research rather than a successful Phase 3 trial in sudden sensorineural hearing loss.
How might ebselen protect the inner ear from inflammatory injury?
SPI-1005 contains ebselen, an organoselenium compound investigated for antioxidant and anti-inflammatory activity. The molecule is designed to mimic aspects of glutathione peroxidase function, a family of enzymes involved in controlling oxidative stress. These enzymes help protect cells from damage associated with reactive oxygen species and other harmful chemical processes.
Inner ear structures contain specialized sensory cells and supporting tissues that are vulnerable to oxidative and inflammatory injury. Damage to these structures can affect the conversion of sound vibrations into neural signals. Their limited capacity for regeneration in humans contributes to the difficulty of reversing many forms of sensorineural hearing loss.
Sound Pharmaceuticals is investigating whether ebselen can support cellular protection and recovery by influencing these pathways. The proposed mechanism differs from treatments primarily intended to suppress immune activity through corticosteroid receptors. It may therefore offer a separate therapeutic strategy if clinical studies establish benefit.
However, evidence of antioxidant activity does not automatically demonstrate regeneration of damaged hair cells or restoration of lost auditory neurons. Improvement in hearing measurements may reflect several biological processes, including changes in inflammation or the function of surviving cells. The company has not demonstrated that SPI-1005 regenerates human inner ear sensory cells.
The mechanistic rationale is scientifically relevant, but clinical effectiveness must be determined through appropriate patient outcomes rather than inferred from antioxidant properties alone.
Why could low-to-mid-frequency hearing recovery matter for patients?
Pure-tone audiometry measures the quietest sounds a person can detect at different frequencies. Improvements in threshold measurements can indicate changes in auditory sensitivity, potentially affecting how patients perceive speech and environmental sounds. However, a numerical improvement in decibels does not necessarily correspond directly with the same degree of everyday communication benefit.
Low-frequency hearing contributes to several aspects of sound perception, while mid-frequency hearing is particularly relevant to components of speech. Patients may experience substantial difficulty understanding conversation even when hearing thresholds are relatively preserved at some frequencies. This is one reason researchers also evaluate speech discrimination.
The words-in-noise test examines how well participants recognize speech under challenging listening conditions. It can provide additional information about functional hearing beyond the ability to detect simple tones. The STOPMD-3 finding of improved response rates on this measure therefore strengthens the clinical relevance of the audiometry results.
Nevertheless, the new October analysis does not provide a complete dataset linking the three-to-four-frequency improvement criterion with individual quality-of-life outcomes. It also does not establish whether the measured gains are durable after extended periods without treatment. Those questions will be important in future development.
For patients experiencing sudden hearing loss, timing is especially consequential. A treatment may have different effects when administered shortly after an acute injury compared with treatment months or years later. The Ménière’s findings cannot determine the optimal treatment window in sudden sensorineural hearing loss.
How does SPI-1005 compare with existing treatment approaches for sudden hearing loss?
Current management of sudden sensorineural hearing loss emphasizes rapid assessment and appropriate identification of potential causes. Clinical guidance recommends audiometric confirmation as soon as possible, generally within 14 days of symptom onset. Patients may also require evaluation for conditions affecting the auditory nerve or other structures beyond the inner ear.
Corticosteroids are commonly considered during the early treatment period. The American Academy of Otolaryngology-Head and Neck Surgery’s clinical guideline states that clinicians may offer corticosteroids within two weeks of symptom onset. Intratympanic steroid treatment is recommended as an option for patients with incomplete recovery during a defined later window.
Hyperbaric oxygen therapy may also be considered in selected patients when combined with corticosteroids and delivered within appropriate time frames. However, access, suitability and the underlying evidence vary. Treatment decisions therefore require clinical assessment rather than reliance on one standard regimen for every patient.
SPI-1005 could eventually offer an oral treatment option based on a different biological mechanism. Its use might be investigated alone or alongside existing approaches, but no approved regimen for sudden sensorineural hearing loss has been established. The company has not announced a completed randomized pivotal study directly comparing SPI-1005 with corticosteroids in acute sudden hearing loss.
Until condition-specific evidence becomes available, patients should not interpret the Ménière’s trial results as a reason to delay the urgent evaluation of sudden hearing changes.
What does the FDA’s Breakthrough Therapy designation mean for SPI-1005?
Sound Pharmaceuticals received FDA Breakthrough Therapy designation in late 2025 for SPI-1005 in the treatment of hearing loss associated with Ménière’s disease. The designation followed the company’s Phase 3 clinical programme and its reported improvements in auditory outcomes. It is intended to facilitate the development and review of medicines showing preliminary evidence of substantial improvement over available therapies for serious conditions.
The company has also disclosed Fast Track designation for the Ménière’s programme. These designations can support closer regulatory communication and potentially more efficient development. However, they are not marketing approvals and do not authorize commercial use.
The regulatory distinction is especially important because the October 2026 announcement discusses potential application to sudden sensorineural hearing loss. The existing designations concern the stated Ménière’s disease development programme and should not automatically be treated as approval or designation for every other auditory indication. Each proposed indication requires an appropriate clinical and regulatory strategy.
Sound Pharmaceuticals reported that SPI-1005 had been studied across 15 ongoing and completed trials involving more than 980 participants in different conditions. This provides broader exposure information, although participants were not all treated for the same disease. The overall clinical experience cannot substitute for establishing efficacy in sudden sensorineural hearing loss.
What is the significance of the additional open-label Phase 3 study?
In July 2026, Sound Pharmaceuticals announced completion of enrollment in a second Phase 3 study involving open-label treatment of Ménière’s disease. The programme builds on STOPMD-3 and reflects the company’s interest in longer-term treatment experience. However, an open-label design differs from a randomized blinded comparison because participants and investigators know that active treatment is being administered.
The earlier pivotal trial also included an open-label extension. Of the 221 randomized participants, 201 entered an extension lasting up to six months, while 107 continued into a later extension period of up to 12 months. These observations may provide information about continued treatment and longer-term tolerability.
The company reported improvements in several patient-reported symptoms during the extension, including tinnitus, vertigo, ear fullness and dizziness. However, without a continuing randomized placebo group, changes during open-label follow-up cannot establish the magnitude of the treatment effect relative to untreated disease. Symptom fluctuations and patient selection can influence the results.
The additional study may strengthen the overall evidence package concerning repeated administration. It does not establish the benefit of SPI-1005 in sudden sensorineural hearing loss, nor does it substitute for a dedicated acute hearing loss trial.
What must Sound Pharmaceuticals establish before expanding into sudden hearing loss?
The immediate scientific question is whether the hearing improvements observed in Ménière’s disease reflect mechanisms relevant to patients with acute sudden sensorineural hearing loss. The new AAO-HNS analysis provides a rationale for investigating overlapping frequency ranges and functional hearing outcomes. However, patients would need to be enrolled according to the diagnostic criteria and treatment timing relevant to sudden hearing loss.
A dedicated clinical programme should establish the appropriate dosing schedule, treatment window and comparator. Relevant outcomes could include recovery measured by pure-tone audiometry, speech discrimination and the proportion of patients achieving clinically meaningful hearing improvement. Longer follow-up would help determine whether any benefit is sustained.
Safety is also important because the proposed population may include patients with different medical conditions and exposure to corticosteroids or other treatments. Although the company reports that extensive clinical experience has not identified significant drug-drug interactions, this does not eliminate the need for combination-specific assessment. The October announcement does not disclose a completed safety dataset for SPI-1005 in patients receiving treatment specifically for acute sudden hearing loss.
Sound Pharmaceuticals’ latest presentation adds analytical depth to its established Phase 3 findings and has received recognition from a major professional society. The reported improvements in hearing thresholds and speech discrimination support continued investigation of ebselen-based treatment for inner ear disorders.
The principal limitation remains the gap between the studied disease and the proposed new indication. Evidence from Ménière’s disease can inform trial design and biological hypotheses, but it cannot establish that SPI-1005 restores hearing after an acute sudden loss. That conclusion will require a dedicated clinical study demonstrating benefit in the intended patient population.
